Theriva Biologics (TOVX) Net Equity Issued and Repurchased (2010 - 2025)
Theriva Biologics (TOVX) posted quarterly Net Equity Issued and Repurchased of $110000.0 for Q4 2025, down 93.32% year-over-year from $1.6 million in Q4 2024, and down 60.57% quarter-over-quarter from $279000.0 in Q3 2025.
Theriva Biologics (TOVX) Net Equity Issued and Repurchased (2010 - 2025) Analysis & Trends
Theriva Biologics (TOVX) has reported Net Equity Issued and Repurchased for 12 consecutive years, with $110000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased fell 93.32% year-over-year to $110000.0; the TTM figure through Dec 2025 stood at $3.8 million (up 11.25% YoY), while the FY2025 annual figure was $6.8 million, up 88.89% from the prior year.
- Net Equity Issued and Repurchased declined to $110000.0 in Q4 2025 per TOVX's latest filing, from $279000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $66.0 million in Q1 2021 and bottomed at -$40000.0 in Q2 2021.
- Historically, Net Equity Issued and Repurchased has averaged $10.0 million across 4 years, with a median of $279000.0 in 2025.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased jumped 179900.0% — and 2025, when it slumped 93.32%.
- Theriva Biologics' Net Equity Issued and Repurchased stood at -$40000.0 in 2021, then surged by 102.5% to $1000.0 in 2023, then jumped by 164600.0% to $1.6 million in 2024, then plunged by 93.32% to $110000.0 in 2025.
- Business Quant data shows TOVX's Net Equity Issued and Repurchased at $110000.0 in Q4 2025, $279000.0 in Q3 2025, and $1.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110,000.00 |
| Dec 31, 2025 | 110,000.00 |
| Sep 30, 2025 | 279,000.00 |
| Sep 30, 2025 | 279,000.00 |
| Dec 31, 2024 | 1.65 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2021 | -40,000.00 |
| Jun 30, 2021 | -40,000.00 |
| Mar 31, 2021 | 66.00 Mn |
| Mar 31, 2021 | 66.00 Mn |
| Dec 31, 2020 | 3.36 Mn |
| Dec 31, 2020 | 3.36 Mn |
| Dec 31, 2018 | 5.75 Mn |
| Dec 31, 2018 | 5.75 Mn |
| Sep 30, 2018 | 6.00 Mn |
| Sep 30, 2018 | 6.00 Mn |